Understanding cardiovascular injury after treatment for cancer: An overview of current uses and future directions of cardiovascular magnetic resonance

Journal of Cardiovascular Magnetic Resonance

Volumn 15, Issue 1, 2013, Pages

  Vasu, Sujethra ^a   Hundley, W Gregory ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Cardiotoxicity; Cardiovascular magnetic resonance; Chemotherapy

Indexed keywords

ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; ARSENIC TRIOXIDE; BEVACIZUMAB; BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IDARUBICIN; IFOSFAMIDE; IMATINIB; INTERLEUKIN 2; LAPATINIB; MITOXANTRONE; PACLITAXEL; PENTOSTATIN; RETINOIC ACID; SORAFENIB; SUNITINIB; TRASTUZUMAB; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ARTERIAL THROMBOEMBOLISM; ATRIOVENTRICULAR BLOCK; AUTONOMIC NEUROPATHY; BRADYCARDIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; CANCER THERAPY; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INJURY; CARDIOVASCULAR MAGNETIC RESONANCE; CEREBROVASCULAR ACCIDENT; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; EXERCISE; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GERM CELL TUMOR; HAIRY CELL LEUKEMIA; HEART; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FUNCTION; HUMAN; HYPERTENSION; HYPOTENSION; KAPOSI SARCOMA; KIDNEY CARCINOMA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG FIBROSIS; LYMPHOMA; MELANOMA; MICROANGIOPATHY; MYOCARDITIS; NEPHROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERICARDIAL EFFUSION; PERICARDITIS; PRIMARY PREVENTION; PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; RAYNAUD PHENOMENON; REVIEW; SARCOMA; SOLID TUMOR; STOMACH CANCER; THROMBOEMBOLISM; THROMBOSIS; VENOUS THROMBOEMBOLISM; ANIMAL; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CHEMICALLY INDUCED; DRUG EFFECTS; EARLY DIAGNOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SURVIVOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; EARLY DIAGNOSIS; HUMANS; MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVORS;

EID: 84880887347     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-15-66     Document Type: Review

References (118)

1. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, et al. J Natl Cancer Inst 2012 104 1293 305 10.1093/jnci/djs317 22949432
2. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Brenner H, Lancet 2002 360 1131 5 10.1016/S0140-6736(02)11199-8 12387961 (Pubitemid 35246487)
3. Breast cancer as a global health concern. Coughlin SS, Ekwueme DU, Cancer Epidemiol 2009 33 315 8 10.1016/j.canep.2009.10.003 19896917
4. Competing causes of death for women with breast cancer and change over time from 1975 to 2003. Du XL, Fox EE, Lai D, Am J Clin Oncol 2008 31 105 16 10.1097/COC.0b013e318142c865 18391593 (Pubitemid 351519161)
5. Trastuzumab and congestive heart failure: what can we learn from use in the community? Geiger AM, J Natl Cancer Inst 2012 104 1269 70 22949431
6. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, Taylor CW, van Leeuwen FE, J Natl Cancer Inst 2007 99 365 75 10.1093/jnci/djk064 17341728 (Pubitemid 47073480)
7. Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy. Maurea N, Coppola C, Ragone G, Frasci G, Bonelli A, Romano C, Iaffaioli RV, J Cardiovasc Med (Hagerstown) 2010 11 861 8 10.2459/JCM.0b013e328336b4c1
8. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD, Breast Cancer Res 2011 13 64 10.1186/bcr2901 21689398
9. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH, J Clin Oncol 2007 25 3808 15 10.1200/JCO.2006.10. 4976 17664460 (Pubitemid 47477254)
10. Health profiles in 5836 long-term cancer survivors. Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R, Int J Cancer 2003 104 488 95 10.1002/ijc.10981 12584748 (Pubitemid 36323921)
11. Incidence of cardiovascular events in breast cancer patients receiving chemotherapy in clinical practice. Sukel MP, Breekveldt-Postma NS, Erkens JA, van der Linden PD, Beiderbeck AB, Coebergh JW, Herings RM, Pharmacoepidemiol Drug Saf 2008 17 125 34 10.1002/pds.1528 18058835 (Pubitemid 351308511)
12. Cardiovascular outcomes in women with advanced breast cancer exposed to chemotherapy. Yood MU, Wells KE, Alford SH, Dakki H, Beiderbeck AB, Hurria A, Gross CP, Oliveria SA, Pharmacoepidemiol Drug Saf 2012 21 818 27 10.1002/pds.3239 22419528
13. SEER Cancer Statistics Review, 1975-2008 http://seer.cancer.gov/csr/1975- 2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011 18718969
14. Cancer Facts & Figures 2012 http://www.cancer.org/acs/groups/content/ @epidemiologysurveilance/documents/document/acspc-031941.pdf 23910930
15. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A, BMC Cancer 2010 10 337 10.1186/1471-2407-10-337 20587042
16. Cardiac dysfunction in the trastuzumab clinical trials experience. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D, J Clin Oncol 2002 20 1215 21 10.1200/JCO.20.5.1215 11870163 (Pubitemid 34177427)
17. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Keating NL, O'Malley AJ, Smith MR, J Clin Oncol 2006 24 27 4448 56 10.1200/JCO.2006.06.2497 16983113 (Pubitemid 46630983)
18. Cardiac mortality in patients with stage I and II diffuse large B-cell lymphoma treated with and without radiation: a surveillance, epidemiology, and end-results analysis. Pugh TJ, Ballonoff A, Rusthoven KE, McCammon R, Kavanagh B, Newman F, Rabinovitch R, Int J Radiat Oncol Biol Phys 2010 76 845 9 10.1016/j.ijrobp.2009.02.045 19515509
19. Risk of ischemic heart disease in women after radiotherapy for breast cancer. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, et al. N Engl J Med 2013 368 987 998 10.1056/NEJMoa1209825 23484825
20. Cardiovascular risk factors in adult survivors of pediatric cancer-a report from the childhood cancer survivor study. Meacham LR, Chow EJ, Ness KK, Kamdar KY, Chen Y, Yasui Y, Oeffinger KC, Sklar CA, Robison LL, Mertens AC, Cancer Epidemiol Biomarkers Prev 2010 19 170 81 10.1158/1055-9965.EPI-09-0555 20056636
21. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL, J Clin Oncol 2005 23 8597 605 10.1200/JCO.2005.02.5841 16314622 (Pubitemid 46211501)
22. Chronic disease in the childhood cancer survivor study cohort: a review of published findings. Diller L, Chow EJ, Gurney JG, Hudson MM, Kadin-Lottick NS, Kawashima TI, Leisenring WM, Meacham LR, Mertens AC, Mulrooney DA, et al. J Clin Oncol 2009 27 2339 55 10.1200/JCO.2008.21.1953 19364955
23. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ, J Clin Oncol 2006 24 4107 15 10.1200/JCO.2005.04.9551 16908934 (Pubitemid 46622286)
24. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, Donaldson SS, Green DM, Sklar CA, Robison LL, Leisenring WM, BMJ 2009 339 4606 10.1136/bmj.b4606 19996459
25. Clinical cardiac tolerability of trastuzumab. Perez EA, Rodeheffer R, J Clin Oncol 2004 22 322 9 14722042 (Pubitemid 41095098)
26. Cardiovascular risk and insulin resistance in childhood cancer survivors. Steinberger J, Sinaiko AR, Kelly AS, Leisenring WM, Steffen LM, Goodman P, Mulrooney DA, Dietz AC, Moran A, Perkins JL, Baker KS, J Pediatr 2011 160 494 9 21920542
27. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, Hoskin PJ, Lister A, Radford JA, Rohatiner AZ, Linch DC, J Natl Cancer Inst 2007 99 206 14 10.1093/jnci/djk029 17284715
28. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, Tarbell NJ, Friedberg J, Canellos GP, Mauch PM, J Clin Oncol 2002 20 2101 8 10.1200/JCO.2002.08.021 11956271 (Pubitemid 34408801)
29. Excess of cardiovascular mortality among node-negative breast cancer patients irradiated for inner-quadrant tumors. Bouchardy C, Rapiti E, Usel M, Majno SB, Vlastos G, Benhamou S, Miralbell R, Neyroud-Caspar I, Verkooijen HM, Vinh-Hung V, Ann Oncol 2010 21 459 65 10.1093/annonc/mdp341 19703922
30. Long-term cardiovascular mortality after radiotherapy for breast cancer. Bouillon K, Haddy N, Delaloge S, Garbay JR, Garsi JP, Brindel P, Mousannif A, Lê MG, Labbe M, Arriagada R, et al. J Am Coll Cardiol 2011 57 445 52 10.1016/j.jacc.2010.08.638 21251585
31. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A, Prog Cardiovasc Dis 2010 53 94 104 10.1016/j.pcad.2010.05.006 20728696
32. Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study. Roychoudhuri R, Robinson D, Putcha V, Cuzick J, Darby S, Møller H, BMC Cancer 2007 7 9 10.1186/1471-2407-7-9 17224064 (Pubitemid 46242723)
33. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. Yeh ET, Bickford CL, J Am Coll Cardiol 2009 53 2231 47 10.1016/j.jacc.2009.02.050 19520246
34. ErbB2 is essential in the prevention of dilated cardiomyopathy. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, et al. Nat Med 2002 8 459 65 10.1038/nm0502-459 11984589 (Pubitemid 34546747)
35. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. N Engl J Med 2001 344 783 92 10.1056/NEJM200103153441101 11248153 (Pubitemid 32222155)
36. Adjuvant trastuzumab in HER2-positive breast cancer. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et al. N Engl J Med 2011 365 1273 83 10.1056/NEJMoa0910383 21991949
37. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al. N Engl J Med 2005 353 1659 72 10.1056/NEJMoa052306 16236737 (Pubitemid 41464705)
38. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, et al. J Clin Oncol 2005 23 7811 9 10.1200/JCO.2005.02.4091 16258083 (Pubitemid 46657378)
39. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A, J Natl Cancer Inst 2011 103 1299 309 10.1093/jnci/djr242 21743022
40. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, et al. N Engl J Med 2003 349 1793 802 10.1056/NEJMoa032312 14551341 (Pubitemid 37362955)
41. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. Huggins C, Hodges CV, J Urol 2002 168 9 12 10.1016/S0022- 5347(05)64820-3 12050481
42. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, et al. N Engl J Med 2005 353 2747 57 16382061 (Pubitemid 43016814)
43. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. Chapman JA, Meng D, Shepherd L, Parulekar W, Ingle JN, Muss HB, Palmer M, Yu C, Goss PE, J Natl Cancer Inst 2008 100 252 60 10.1093/jnci/djn014 18270335 (Pubitemid 351480540)
44. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Ewer MS, Gluck S, Cancer 2009 115 1813 26 10.1002/cncr.24219 19235248
45. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Hu JC, Williams SB, O'Malley AJ, Smith MR, Nguyen PL, Keating NL, Eur Urol 2012
46. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. Keating NL, O'Malley AJ, Freedland SJ, Smith MR, J Natl Cancer Inst 2010 102 39 46 10.1093/jnci/djp404 19996060
47. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, Lambe M, Stattin P, Adolfsson J, J Clin Oncol 2010 28 3448 56 10.1200/JCO.2010.29.1567 20567006
48. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Azoulay L, Yin H, Benayoun S, Renoux C, Boivin JF, Suissa S, Eur Urol 2011 60 1244 50 10.1016/j.eururo.2011.08.041 21908097
49. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM, Lancet Oncol 2006 7 633 43 16887480
50. Detection of anthracycline-induced cardiotoxicity. Meinardi MT, van der Graaf WT, van Veldhuisen DJ, Gietema JA, de Vries EG, Sleijfer DT, Cancer Treat Rev 1999 25 237 47 10.1053/ctrv.1999.0128 10448132 (Pubitemid 29417681)
51. Anthracycline cardiomyopathy monitored by morphologic changes. Billingham ME, Mason JW, Bristow MR, Daniels JR, Cancer Treat Rep 1978 62 865 72 667860 (Pubitemid 8377880)
52. Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. Isner JM, Ferrans VJ, Cohen SR, Witkind BG, Virmani R, Gottdiener JS, Beck JR, Roberts WC, Am J Cardiol 1983 51 1167 74 10.1016/0002-9149(83)90364-8 6573121 (Pubitemid 13161382)
53. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L, Duffy T, Schwartz P, Gottschalk A, Zaret BL, N Engl J Med 1979 300 278 83 10.1056/NEJM197902083000603 759880 (Pubitemid 9115687)
54. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K, Am Heart J 1983 106 1048 56 10.1016/0002-8703(83)90651-8 6637763 (Pubitemid 14229682)
55. Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. Gottdiener JS, Mathisen DJ, Borer JS, Bonow RO, Myers CE, Barr LH, Schwartz DE, Bacharach SL, Green MV, Rosenberg SA, Ann Intern Med 1981 94 430 5 10.7326/0003-4819-94-4-430 7212498 (Pubitemid 11103937)
56. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the cardiovascular disease task force of the children's oncology group. Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Landier W, Bhatia S, Meeske K, Chen MH, Kinahan KE, et al. Pediatrics 2008 121 387 96 10.1542/peds.2007-0575 18187811 (Pubitemid 351198462)
57. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the cardiology committee of the childrens cancer study group. Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, Sandor G, Benson L, Williams R, Pediatrics 1992 89 942 9 1579408
58. 31P NMR spectroscopy in chronic adriamycin cardiotoxicity. Bittner V, Reeves RC, Digerness SB, Caulfield JB, Pohost GM, Magn Reson Med 1991 17 69 81 10.1002/mrm.1910170112 2067408
59. Troponin I and cardiovascular risk stratification in patients with testicular cancer. Cardinale D, Lamantia G, Cipolla CM, J Clin Oncol 2006 24 3508 9 16849772
60. Review: role of biomarkers in cardioncology. Cardinale D, Salvatici M, Sandri MT, Clin Chem Lab Med 2011 49 1937 48 21892906
61. Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy. Cardinale D, Colombo A, Cipolla CM, Curr Treat Options Cardiovasc Med 2008 10 486 95 10.1007/s11936-008-0041-x 19026179
62. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM, Circulation 2006 114 2474 81 10.1161/CIRCULATIONAHA.106.635144 17101852 (Pubitemid 44901520)
63. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. Hendel RC, Patel MR, Kramer CM, Poon M, Carr JC, Gerstad NA, Gillam LD, Hodgson JM, Kim RJ, Lesser JR, et al. J Am Coll Cardiol 2006 48 1475 97 10.1016/j.jacc.2006.07.003 17010819
64. Aortic stiffness increases upon receipt of anthracycline chemotherapy. Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG, J Clin Oncol 2010 28 166 72 10.1200/JCO.2009.23.8527 19901105
65. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, van Rossum AC, Shaw LJ, Yucel EK, J Cardiovasc Magn Reson 2004 6 727 65 10.1081/JCMR-200038581 15646878 (Pubitemid 40041279)
66. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, Tian G, Kirkpatrick ID, Singal PK, Krahn M, et al. J Am Coll Cardiol 2011 57 2263 70 10.1016/j.jacc.2010.11.063 21616287
67. Imaging for cardiotoxicity in cancer patients. Banchs J, Jefferies JL, Plana JC, Hundley WG, Tex Heart Inst J 2011 38 268 9 21720469
68. Radiation-associated cardiovascular disease. Adams MJ, Hardenbergh PH, Constine LS, Lipshultz SE, Crit Rev Oncol Hematol 2003 45 55 75 10.1016/S1040-8428(01)00227-X 12482572 (Pubitemid 35449788)
69. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Schellong G, Riepenhausen M, Bruch C, Kotthoff S, Vogt J, Bolling T, Dieckmann K, Potter R, Heinecke A, Bramswig J, Dorffel W, Pediatr Blood Cancer 2010 55 1145 52 10.1002/pbc.22664 20734400
70. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Galper SL, Yu JB, Mauch PM, Strasser JF, Silver B, Lacasce A, Marcus KJ, Stevenson MA, Chen MH, Ng AK, Blood 2011 117 412 8 10.1182/blood-2010-06-291328 20858859
71. Metastatic involvement of the heart and pericardium: CT and MR imaging. Chiles C, Woodard PK, Gutierrez FR, Link KM, Radiographics 2001 21 439 49 11259706 (Pubitemid 33707769)
72. Neoplasms metastatic to the heart: review of 3314 consecutive autopsies. Abraham KP, Reddy V, Gattuso P, Am J Cardiovasc Pathol 1990 3 195 8 2095826
73. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Mason JW, Bristow MR, Billingham ME, Daniels JR, Cancer Treat Rep 1978 62 857 64 667859 (Pubitemid 8377879)
74. Adriamycin cardiotoxicity and proton nuclear magnetic resonance relaxation properties. Thompson RC, Canby RC, Lojeski EW, Ratner AV, Fallon JT, Pohost GM, Am Heart J 1987 113 1444 9 10.1016/0002-8703(87)90660-0 3591613 (Pubitemid 17092817)
75. Early incidence of adriamycin treatment on cardiac parameters in the rat. Cottin Y, Ribuot C, Maupoil V, Godin D, Arnould L, Brunotte F, Rochette L, Can J Physiol Pharmacol 1994 72 140 5 10.1139/y94-022 8050054 (Pubitemid 24156228)
76. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study. Wassmuth R, Lentzsch S, Erdbruegger U, Schulz-Menger J, Doerken B, Dietz R, Friedrich MG, Am Heart J 2001 141 1007 13 10.1067/mhj.2001.115436 11376317 (Pubitemid 32477014)
77. Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model. Lightfoot JC, D'Agostino RB Jr, Hamilton CA, Jordan J, Torti FM, Kock ND, Workman S, Hundley WG, Circ Cardiovasc Imaging 2010 3 550 8 10.1161/CIRCIMAGING.109.918540 20622140
78. Quantification of diffuse myocardial fibrosis and its association with myocardial dysfunction in congenital heart disease. Broberg CS, Chugh SS, Conklin C, Sahn DJ, Jerosch-Herold M, Circ Cardiovasc Imaging 2010 3 727 34 10.1161/CIRCIMAGING.108.842096 20855860
79. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Jerosch-Herold M, Sheridan DC, Kushner JD, Nauman D, Burgess D, Dutton D, Alharethi R, Li D, Hershberger RE, Am J Physiol Heart Circ Physiol 2008 295 1234 42 10.1152/ajpheart.00429.2008 18660445
80. Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus. Schelbert EB, Testa SM, Meier CG, Ceyrolles WJ, Levenson JE, Blair AJ, Kellman P, Jones BL, Ludwig DR, Schwartzman D, et al. J Cardiovasc Magn Reson 2011 13 16 10.1186/1532-429X-13-16 21375743
81. Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. Messroghli DR, Greiser A, Fröhlich M, Dietz R, Schulz-Menger J, J Magn Reson Imaging 2007 26 1081 6 10.1002/jmri.21119 17896383 (Pubitemid 47548170)
82. Human myocardium: single-breath-hold MR T1 mapping with high spatial resolution-reproducibility study. Messroghli DR, Plein S, Higgins DM, Walters K, Jones TR, Ridgway JP, Sivananthan MU, Radiology 2006 238 1004 12 10.1148/radiol.2382041903 16424239 (Pubitemid 43289933)
83. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP, Magn Reson Med 2004 52 141 6 10.1002/mrm.20110 15236377 (Pubitemid 39295266)
84. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC, Circulation 2010 122 138 44 10.1161/CIRCULATIONAHA.109.930636 20585010
85. Effectiveness of late gadolinium enhancement to improve outcomes prediction in patients referred for cardiovascular magnetic resonance after echocardiography. Wong TC, Piehler K, Puntil KS, Moguillansky D, Meier CG, Lacomis JM, Kellman P, Cook SC, Schwartzman DS, Simon MA, et al. J Cardiovasc Magn Reson 2013 15 6 10.1186/1532-429X-15-6 23324403
86. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Schwartz RG, McKenzie WB, Alexander J, Sager P, D'Souza A, Manatunga A, Schwartz PE, Berger HJ, Setaro J, Surkin L, et al. Am J Med 1987 82 1109 18 10.1016/0002-9343(87)90212-9 3605130
87. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD, Plummer CJ, Wardley AM, Verrill MW, Br J Cancer 2009 100 684 92 10.1038/sj.bjc.6604909 19259090
88. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Bovelli D, Plataniotis G, Roila F, Ann Oncol 2010 21 Suppl 5 82 20555097
89. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, Pennell DJ, Am J Cardiol 2002 90 29 34 10.1016/S0002-9149(02)02381-0 12088775 (Pubitemid 34671198)
90. Left ventricular measurements with cine and spin-echo MR imaging: a study of reproducibility with variance component analysis. Pattynama PM, Lamb HJ, van der Velde EA, van der Wall EE, de Roos A, Radiology 1993 187 261 8 8451425 (Pubitemid 23097896)
91. Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. Stoodley PW, Richards DA, Hui R, Boyd A, Harnett PR, Meikle SR, Clarke J, Thomas L, Eur J Echocardiogr 2011 12 945 52 10.1093/ejechocard/jer187 21965152
92. Incremental prognostic value of assessing left ventricular myocardial mechanics in patients with chronic systolic heart failure. Motoki H, Borowski AG, Shrestha K, Troughton RW, Tang WH, Thomas JD, Klein AL, J Am Coll Cardiol 2012 60 2074 81 10.1016/j.jacc.2012.07.047 23083779
93. Global 2-dimensional strain as a new prognosticator in patients with heart failure. Cho GY, Marwick TH, Kim HS, Kim MK, Hong KS, Oh DJ, J Am Coll Cardiol 2009 54 618 24 10.1016/j.jacc.2009.04.061 19660692
94. Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosis (Al). Bellavia D, Abraham RS, Pellikka PA, Dispenzieri A, Burnett JC Jr, Al-Zahrani GB, Green TD, Manske MK, Gertz MA, Miller FA Jr, Abraham TP, J Am Soc Echocardiogr 2011 24 444 54 10.1016/j.echo.2011.01.003 21315556
95. Clinical significance of global two-dimensional strain as a surrogate parameter of myocardial fibrosis and cardiac events in patients with hypertrophic cardiomyopathy. Saito M, Okayama H, Yoshii T, Higashi H, Morioka H, Hiasa G, Sumimoto T, Inaba S, Nishimura K, Inoue K, et al. Eur Heart J Cardiovasc Imaging 2012 13 617 23 10.1093/ejechocard/jer318 22271116
96. Low to moderate dose anthracyline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. Drafts BC, Twomley KM, D'Agostino RB, Lawrence JA, Avis NE, Ellis LR, Thohan V, Jordan J, Melin SA, Torti FM, et al. JACC Cardiovasc Imaging 2012 Accepted for publication 10.1016/j.jcmg.2012.11.017
97. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101-Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. Pituskin E, Haykowsky M, Mackey JR, Thompson RB, Ezekowitz J, Koshman S, Oudit G, Chow K, Pagano JJ, Paterson I, BMC Cancer 2011 11 318 10.1186/1471-2407-11-318 21794114
98. Reproducibility of in-vivo diffusion tensor cardiovascular magnetic resonance in hypertrophic cardiomyopathy. McGill LA, Ismail TF, Nielles-Vallespin S, Ferreira P, Scott AD, Roughton M, Kilner PJ, Ho SY, McCarthy KP, Gatehouse PD, et al. J Cardiovasc Magn Reson 2012 14 86 10.1186/1532-429X-14-86 23259835
99. Effects of weight loss on myocardial energetics and diastolic function in obesity. Rider OJ, Francis JM, Tyler D, Byrne J, Clarke K, Neubauer S, Int J Cardiovasc Imaging 2013 29 5 1043 50 10.1007/s10554-012-0174-6 23269470
100. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS, Cancer 2007 110 1493 500 10.1002/cncr.22933 17657815 (Pubitemid 47463063)
101. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, et al. Lancet 2007 370 2011 9 10.1016/S0140-6736(07)61865-0 18083403 (Pubitemid 350236338)
102. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, et al. J Clin Oncol 2009 27 3312 8 10.1200/JCO.2008.19.5511 19451442
103. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE, N Engl J Med 2007 357 2666 76 10.1056/NEJMoa072113 18160686
104. Weekly Doxorubicin increases coronary arteriolar wall and adventitial thickness. Eckman DM, Stacey RB, Rowe R, D. Agostino RJ, Kock ND, Sane DC, Torti FM, Yeboah J, Workman S, Lane KS, Hundley WG, PLoS One 2013 8 57554 10.1371/journal.pone.0057554 23437398
105. Relation of aortic distensibility determined by magnetic resonance imaging in patients > or =60 years of age to systolic heart failure and exercise capacity. Rerkpattanapipat P, Hundley WG, Link KM, Brubaker PH, Hamilton CA, Darty SN, Morgan TM, Kitzman DW, Am J Cardiol 2002 90 1221 5 10.1016/S0002-9149(02)02838-2 12450602 (Pubitemid 35346879)
106. Fatigue in breast cancer survivors two to five years post diagnosis: a HEAL Study report. Meeske K, Smith AW, Alfano CM, McGregor BA, McTiernan A, Baumgartner KB, Malone KE, Reeve BB, Ballard-Barbash R, Bernstein L, Qual Life Res 2007 16 947 60 10.1007/s11136-007-9215-3 17457697 (Pubitemid 47174897)
107. Nonanatomic prognostic factors in carcinoma of the lung: a multivariate analysis. Pater JL, Loeb M, Cancer 1982 50 326 31 10.1002/1097-0142(19820715)50: 2<326::AID-CNCR2820500227>3.0.CO;2-G 7083139 (Pubitemid 12089395)
108. Prognostic factors and survival in a heterogeneous sample of cancer patients. Ringdal GI, Gotestam KG, Kaasa S, Kvinnsland S, Ringdal K, Br J Cancer 1996 73 1594 9 10.1038/bjc.1996.300 8664136 (Pubitemid 26235390)
109. The effects of a six-week supervised multimodal exercise intervention during chemotherapy on cancer-related fatigue. Andersen C, Rørth M, Ejlertsen B, Stage M, Møller T, Midtgaard J, Quist M, Bloomquist K, Adamsen L, Eur J Oncol Nurs 2013 17 3 331 9 10.1016/j.ejon.2012.09.003 23084254
110. Physical activity and survival after breast cancer diagnosis. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA, JAMA 2005 293 2479 86 10.1001/jama.293.20.2479 15914748 (Pubitemid 40705729)
111. Physical activity and survival after colorectal cancer diagnosis. Meyerhardt JA, Giovannucci EL, Holmes MD, Chan AT, Chan JA, Colditz GA, Fuchs CS, J Clin Oncol 2006 24 3527 34 10.1200/JCO.2006.06.0855 16822844 (Pubitemid 46630522)
112. Leg flow-mediated arterial dilation in elderly patients with heart failure and normal left ventricular ejection fraction. Hundley WG, Bayram E, Hamilton CA, Hamilton EA, Morgan TM, Darty SN, Stewart KP, Link KM, Herrington DM, Kitzman DW, Am J Physiol Heart Circ Physiol 2007 292 1427 34 17085542
113. Reduced peripheral arterial blood flow with preserved cardiac output during submaximal bicycle exercise in elderly heart failure. Puntawangkoon C, Kitzman DW, Kritchevsky SB, Hamilton CA, Nicklas B, Leng X, Brubaker PH, Hundley WG, J Cardiovasc Magn Reson 2009 11 48 10.1186/1532-429X-11-48 19922666
114. Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle. Gilliam LA, Ferreira LF, Bruton JD, Moylan JS, Westerblad H, St Clair DK, Reid MB, J Appl Physiol 2009 107 1935 42 10.1152/japplphysiol.00776.2009 19779154
115. Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy. Gilliam LA, Moylan JS, Ann Callahan L, Sumandea MP, Reid MB, Muscle Nerve 2011 43 94 102 10.1002/mus.21809 21171100
116. Ultrastructural features of Adriamycin-induced skeletal and cardiac muscle toxicity. Doroshow JH, Tallent C, Schechter JE, Am J Pathol 1985 118 288 97 3970141 (Pubitemid 15127685)
117. Skeletal muscle BOLD MRI: from underlying physiological concepts to its usefulness in clinical conditions. Jacobi B, Bongartz G, Partovi S, Schulte AC, Aschwanden M, Lumsden AB, Davies MG, Loebe M, Noon GP, Karimi S, et al. J Magn Reson Imaging 2012 35 1253 65 10.1002/jmri.23536 22588992
118. Calf muscles imaged at BOLD MR: correlation with TcPO2 and flowmetry measurements during ischemia and reactive hyperemia-initial experience. Ledermann HP, Heidecker HG, Schulte AC, Thalhammer C, Aschwanden M, Jaeger KA, Scheffler K, Bilecen D, Radiology 2006 241 477 84 10.1148/radiol.2412050701 16982813 (Pubitemid 44632894)